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Replication kinetics of CVB3-Nancy are unaffected by neomycin treatment. To 146 examine whether neomycin affects the replication kinetics of CVB3-Nancy, we used 147 single-cycle growth curve assays. HeLa cells that were pretreated with or without 148 neomycin were infected with CVB3-Nancy at an MOI of 0.01, and cell-associated viral 149 titers were determined over time. CVB3-Nancy titers were the same for cells treated 150 with or without neomycin at each timepoint analyzed (Fig. 4A ). We next determined 151 whether the presence of an agar overlay could alter the replication kinetics of CVB3-152 Nancy, and whether the presence of neomycin in the agar overlay could alter CVB3-153 Nancy growth. For these experiments, HeLa cells were pretreated with or without 154 neomycin, cells were infected for 30 min with CVB3-Nancy at an MOI of 0.01, followed 155 by addition of an agar overlay with or without neomycin. At 0, 2, 4, 6, or 8 hours post-156 infection, agar overlays were removed, cells were harvested, and cell-associated virus either liquid media or agar overlay, we next determined whether neomycin could alter 161 spread during multiple replication cycles. One million HeLa cells were inoculated with 162 100 PFU of CVB3-Nancy, in the presence or absence of neomycin, and the cells were 163 incubated for 24 h to allow multiple replication cycles to occur. Viral titers in the 164 presence of liquid media showed no differences in viral yield with or without neomycin 165 ( Fig. 4C ). However, when CVB3-Nancy was grown for 24 h in the presence of an agar 166 overlay, a significant increase in viral yield was detected in the presence of neomycin 167 ( Fig. 4D ). Overall these data indicate that a single cycle of replication of CVB3-Nancy 168 was unaffected by neomycin treatment, but titers from multiple cycles were increased by 169 neomycin treatment when agar overlays were present, suggesting neomycin may aid 170 viral spread in the presence of agar. we hypothesized that neomycin enhances viral diffusion by overcoming inhibition by 176 negatively charged compounds in agar overlays. Additionally, we hypothesized that 177 neomycin must be present in the agar overlay to enhance plaque formation and that 178 pre-treatment of cells with neomycin would not be sufficient to increase plaque size 179 when neomycin was not present in agar overlays. To test this, we pretreated cells with 180 or without neomycin, infected with 100 PFU of CVB3-Nancy and added an agar overlay 181 with or without neomycin. We found that large plaques formed in cells with neomycin in Faculty Scholar grant from the Howard Hughes Medical Institute. MWA was supported 321 in part by NIH NIAID grant T32 AI007520. 
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HeLa cells were pretreated with or without neomycin and were infected with 336 approximately 100 PFU of CVB3-Nancy, CVB3-Nancy-N63Y, or CVB3-H3, and then 337 agar or agarose overlays, containing or lacking 1 mg/ml neomycin, were added. A) Effects of antibiotics on CVB3-Nancy plaque formation. HeLa cells were pretreated with or without 1 mg/ml of the indicated antibiotics prior to plating 100 PFU of CVB3-Nancy on cells with agar overlays with or without 1 mg/ml of each antibiotic. Plates were stained with crystal violet 48 hpi. Abx= ampicillin, neomycin, streptomycin, and vancomycin mixture. Effects of neomycin on CVB3-Nancy (B) or poliovirus (D). C) Plaque size quantification of B. E) Plaque size quantification of D. Each symbol represents a plaque. ****, P<0.0001 (unpaired two-tailed Student t tests). ns= not significant.
Figure 2
Neomycin:
CVB3-H3
Agar Agarose + Figure 2 . Effect of neomycin on plaque formation of different CVB3 strains.
HeLa cells were pretreated with or without neomycin and were infected with approximately 100 PFU of CVB3-Nancy, CVB3-Nancy-N63Y, or CVB3-H3, and then agar or agarose overlays, containing or lacking 1 mg/ml neomycin, were added. HeLa cells that were pretreated with or without neomycin were inoculated with CVB3-Nancy at an MOI of 0.01. Virus was incubated for 30 min at 37°C and either DMEM liquid (A) or 1% Agar/1% DMEM mixture (B) with or without neomycin was added. At indicated timepoints, intracellular virus was harvested and quantified by plaque assay. To examine multi-cycle replication and spread, cells were infected with 100 PFU of CVB3-Nancy and either DMEM (C) or 1% Agar/1% DMEM mixture (D) with or without neomycin followed by plaque assay of cell-associated virus. E) HeLa cells were pretreated with or without 1 mg/ml of neomycin prior to plating 100 PFU of CVB3-Nancy on cells with agar overlays with or without 1 mg/ml of neomycin. Plates were stained with crystal violet 48 hpi. *, P<0.05 (unpaired twotailed Student t tests), ns= not significant. A) 8.8 x 10 6 HeLa cells were infected with 100 PFU of CVB3-Nancy and agar overlays were added with or without 0.1µM poly-L-lysine or 0.8 mg/ml protamine (positively charged compounds). B) 8.8 x 10 6 HeLa cells were infected with 100 PFU of CVB3-Nancy and neomycin-containing agar or agarose overlays were added with or without 1 mg/ml of heparin (negatively charged compound).
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Figure 6
Time (dpi): 1 2 3 Untreated Neomycin Protamine Figure 6 . Effects of positively charged compounds on CVB3-Nancy diffusion. 1 x 10 6 HeLa cells in 60 mm tissue culture plates were overlaid with 4 ml of 1% Agar/1% DMEM mixture that contained or lacked 1 mg/ml neomycin or 0.8 mg/ml protamine. Once the overlay had solidified, 5 x 10 4 PFU of CVB3-Nancy in 200 µL was added dropwise to the top of the overlay. Cells were placed at 37°C to allow diffusion of the virus through the overlay to the cell monolayer and plates were stained with crystal violet at 1, 2, or 3 days post infection (dpi) to reveal the extent of cell death from viral replication.
